Lindus Health Secures ARIA Funding for AI in Clinical Trials

Lindus Health has been awarded funding by the UK's Advanced Research and Invention Agency (ARIA) to develop safe and reliable AI systems for clinical trial design, announced in a press release. This initiative is part of ARIA's Safeguarded AI program, which aims to enhance AI safety in critical sectors like healthcare.

The project, titled "Transforming clinical trial design using safe and reliable AI," will be a collaboration between Lindus Health and the University of Oxford's Department of Computer Science. The focus is on creating AI systems with mathematically proven safeguards to improve decision-making in trial planning. This approach seeks to address inefficiencies and errors in current trial design processes, ultimately reducing setup times and costs while increasing accuracy.

Lindus Health's Head of Product, Nijat Hasanli, emphasized the importance of eliminating risks in trial design to ensure successful outcomes. The project aims to build trust in AI tools among clinical researchers by providing verifiable safety guarantees, potentially reshaping the biopharmaceutical industry's approach to clinical trials.